The financial potential of CANTREAT
According to the European Cancer Information System (ECIS), there were 2.68 million new cancer cases in the EU in 2020 (Austria: 44,294, Germany: 538,140).
Entries by web-artwork.at
Cancer – Numbers and facts
Cancer is one of the most frightening diagnoses today and the numbers continue to rise!
CANTREAT – Medical device or pharmaceutical?
CANTREAT is classified as a medical device: it does not act pharmacologically but serves as a precise distribution method that receives physician-defined pharmaceuticals, transports them to the targeted site, and retains them there.
Chemotherapy – The status today
CANTREAT enables a locally targeted, significantly lower-dose chemotherapy that spares healthy cells, reduces side effects, and thereby improves the immune system, vital functions, and chances of recovery.
CANTREAT enables a locally targeted, significantly lower-dose chemotherapy that spares healthy cells, reduces side effects, and thereby improves the immune system, vital functions, and chances of recovery.
The USP of the CANTREAT-Method
CANTREAT consolidates proven approaches from globally researched drug targeting and, with patent-pending components, new materials, and innovative techniques, delivers an efficient, low-side-effect, locally targeted therapy without costly apparatus—a medical novelty with revolutionary potential.
Tyrolean State Prize for Science awarded to Prof. Dr. Andreas Bernkop-Schnürch
Every year, the province of Tyrol honors a personality from three alternating disciplines who has made outstanding achievements in the field of research and science.
Reward for our specialist
Article in the Tiroler Tageszeitung of August 16th, 2023
Cooperation with the MED-UNI in Innsbruck is working
Together with the Institute of Pharmacy at the Leopold-Franzens University of Innsbruck, the basis for the two most essential research topics considered as USP is being developed in a project funded by the Province of Tyrol.
Social Networks
